Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Merck & Company (MRK)

Tipranks - Tipranks - Tue Apr 21, 6:34AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Reviva Pharmaceuticals Holdings (RVPH) and Merck & Company (MRK) with bullish sentiments.

Claim 30% Off TipRanks

Reviva Pharmaceuticals Holdings (RVPH)

Alliance Global Partners analyst James Molloy reiterated a Buy rating on Reviva Pharmaceuticals Holdings today and set a price target of $30.00. The company’s shares closed last Friday at $0.85, close to its 52-week low of $0.60.

According to TipRanks.com, Molloy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -21.7% and a 25.9% success rate. Molloy covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., Intensity Therapeutics, Inc., and SELLAS Life Sciences Group. ;'>

Reviva Pharmaceuticals Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $15.50.

See today’s best-performing stocks on TipRanks >>

Merck & Company (MRK)

BMO Capital analyst Evan Seigerman maintained a Buy rating on Merck & Company today and set a price target of $135.00. The company’s shares closed last Friday at $119.07.

According to TipRanks.com, Seigerman is a 5-star analyst with an average return of 9.4% and a 52.6% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and Taysha Gene Therapies. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Merck & Company with a $136.37 average price target, a 18.0% upside from current levels. In a report issued on April 6, J.P. Morgan also maintained a Buy rating on the stock with a $135.00 price target.

Read More on RVPH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).